Therapeutic efficacy of ingavirin®, a new Russian formulation against influenza a virus (H3N2)

Antibiotiki i Khimioterapiya

Volumn 53, Issue 7-8, 2008, Pages 27-30

  Loginova, S Ya ^a   Borisevich, S V ^a   Maksimov, V A ^a   Bondarev, V P ^a   Nebolsin, V E ^a  

^a Ministry of Defense of the Russian Federation   (Russian Federation)

Author keywords

Antivirus efficacy; Influenza a virus; Ingavirin ; Therapy

Indexed keywords

AMIDE; ANTIVIRUS AGENT; ARBIDOL; DICARBOXYLIC ACID; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OSELTAMIVIR; PENTANEDIOIC ACID IMIDAZOLYL ETHANAMIDE; RIMANTADINE;

ANIMAL; ARTICLE; COMPARATIVE STUDY; DRUG EFFECT; INFLUENZA VIRUS A H3N2; LUNG; MORTALITY; MOUSE; ORTHOMYXOVIRUS INFECTION; VIROLOGY; VIRUS REPLICATION;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; DICARBOXYLIC ACIDS; IMIDAZOLES; INDOLES; INFLUENZA A VIRUS, H3N2 SUBTYPE; LUNG; MICE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; RIMANTADINE; VIRUS REPLICATION;

INFLUENZA A VIRUS; INFLUENZAVIRUS A; MUS; ORTHOMYXOVIRIDAE;

EID: 59849102706     PISSN: 02352990     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Bright R. A., Medina M. J., Xu X. et at. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994-2005: a cause for concern. Lancet 2005; 366: 9492: 1175-1181.
2. Hay A. J., Zambon M. C, Walstenholme A. J. et at. Molecular basis of resistance of influenza A virus to adamantine. J Antimicrob Chemoter 1986; 18: Suppl B: 19-29.
3. Bright R. A., Shay D. K., Shu B. et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295: 8: 891-894.
4. Deyde V. M., Garten R., Sheu T. et al. Emerging trends in adamantane resistance: 2006-2007 influenza season. Program and Abstract Book International Conference on Emerging Infectious Disease (ICEAD), Atlanta, Georgia (USA) 16-19 March, 2008: 72; http://www.iceid.org/
5. rwww.phacaspc.gc.ca/media/advisories-avis/2006/statment 060115
6. Kiso M., Mitamura K., Sakai-Tagawa Y. et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364: 9436: 759-765.
7. Lacenby A., Hungnes O., Dudman S, G. et al. Emergence of resistance to oseltamivir among influenza A (H1N1) viruses in Europe. Eurosurveillance 2008; 13: Issue 5: 8026.
8. Wetherall et al. Methodology used for testing in vitro susceptibility of influenza viruses to oseltamivir and zanamivir was described by the Neuraminidase Inhibitor Susceptibility Network (NISN). J Clin Microbiol 2003; 41: 742-750.
9. www.euro.who.int/flu/20080131-2
10. www.promedmail.org/Archive Number 20080209.0529. Published date 09-FEB-2008.
11. Leneva I., Hay A. The mechanism of action of arbidol against influenza virus-selection and characterization of arbidol-resistant mutants. Abs. 12th International Congress of Virology. Paris., 2002; 1077.
12. Russian source
13. Russian source